A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (TENAYA)
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Inclusion Criteria:
Exclusion Criteria:
Vancouver, British Columbia V5Z 1M9, Canada
Rome, Lazio 00198, Italy
Milan, Lombardy 20100, Italy
Hokkaido, 060-8604, Japan
Hokkaido, 060-8648, Japan
Hokkaido, 078-8510, Japan
Moscow, Moscow Oblast 119435, Russia
Ankara, 06490, Turkey (Türkiye)